CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
September 24, 2021
Financial
PHARMATHER ANNOUNCES CAD$10 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS
September 21, 2021
Corporate
PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund
September 13, 2021
Corporate
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
September 9, 2021
Corporate
PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 7, 2021
Financial
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021
August 4, 2021
Pipeline
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Amyotrophic Lateral Sclerosis
July 21, 2021
Pipeline
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
June 28, 2021
Corporate
PharmaTher To Participate in Grizzle Psychedelics Con
June 16, 2021
Corporate
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
June 15, 2021
Pipeline
PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression
June 10, 2021
Corporate
PharmaTher Provides Research and Development Update and Milestones for 2021
June 1, 2021
Platform & partnering
PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
May 27, 2021
Platform & partnering
PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover Novel Psychedelic Formulations
May 25, 2021
Pipeline
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
May 20, 2021
Pipeline
Accomplished Clinical Researcher Matthew Macaluso Joins as Scientific and Clinical Advisor for PharmaTher’s Ketamine Programs
May 17, 2021
Pipeline
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
April 27, 2021
Pipeline
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™
April 20, 2021
Pipeline
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease
April 15, 2021
Corporate
PharmaTher Provides Update on Psychedelic Product Programs
March 24, 2021
Pipeline
PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.